CRSP
Price
$66.94
Change
+$1.81 (+2.78%)
Updated
Jul 21, 03:56 PM (EDT)
Capitalization
5.62B
21 days until earnings call
PRME
Price
$4.50
Change
+$0.38 (+9.20%)
Updated
Jul 21, 04:55 PM (EDT)
Capitalization
555.47M
16 days until earnings call
Interact to see
Advertisement

CRSP vs PRME

Header iconCRSP vs PRME Comparison
Open Charts CRSP vs PRMEBanner chart's image
CRISPR Therapeutics AG
Price$66.94
Change+$1.81 (+2.78%)
Volume$1.65K
Capitalization5.62B
Prime Medicine
Price$4.50
Change+$0.38 (+9.20%)
Volume$63.48K
Capitalization555.47M
CRSP vs PRME Comparison Chart in %
Loading...
CRSP
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
PRME
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
CRSP vs. PRME commentary
Jul 21, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is CRSP is a Hold and PRME is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Jul 21, 2025
Stock price -- (CRSP: $65.13 vs. PRME: $4.13)
Brand notoriety: CRSP and PRME are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: CRSP: 323% vs. PRME: 155%
Market capitalization -- CRSP: $5.62B vs. PRME: $555.47M
CRSP [@Biotechnology] is valued at $5.62B. PRME’s [@Biotechnology] market capitalization is $555.47M. The market cap for tickers in the [@Biotechnology] industry ranges from $286.69B to $0. The average market capitalization across the [@Biotechnology] industry is $2.44B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

CRSP’s FA Score shows that 0 FA rating(s) are green whilePRME’s FA Score has 0 green FA rating(s).

  • CRSP’s FA Score: 0 green, 5 red.
  • PRME’s FA Score: 0 green, 5 red.
According to our system of comparison, PRME is a better buy in the long-term than CRSP.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

CRSP’s TA Score shows that 4 TA indicator(s) are bullish while PRME’s TA Score has 3 bullish TA indicator(s).

  • CRSP’s TA Score: 4 bullish, 4 bearish.
  • PRME’s TA Score: 3 bullish, 4 bearish.
According to our system of comparison, CRSP is a better buy in the short-term than PRME.

Price Growth

CRSP (@Biotechnology) experienced а +14.67% price change this week, while PRME (@Biotechnology) price change was -5.06% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +2.79%. For the same industry, the average monthly price growth was +16.27%, and the average quarterly price growth was +35.62%.

Reported Earning Dates

CRSP is expected to report earnings on Aug 11, 2025.

PRME is expected to report earnings on Aug 06, 2025.

Industries' Descriptions

@Biotechnology (+2.79% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
CRSP($5.63B) has a higher market cap than PRME($555M). CRSP YTD gains are higher at: 65.473 vs. PRME (41.438). PRME has higher annual earnings (EBITDA): -200M vs. CRSP (-455.24M). CRSP has more cash in the bank: 1.86B vs. PRME (144M). PRME has less debt than CRSP: PRME (121M) vs CRSP (219M). CRSP has higher revenues than PRME: CRSP (35M) vs PRME (3.85M).
CRSPPRMECRSP / PRME
Capitalization5.63B555M1,014%
EBITDA-455.24M-200M228%
Gain YTD65.47341.438158%
P/E RatioN/AN/A-
Revenue35M3.85M910%
Total Cash1.86B144M1,288%
Total Debt219M121M181%
FUNDAMENTALS RATINGS
CRSP vs PRME: Fundamental Ratings
CRSP
PRME
OUTLOOK RATING
1..100
5050
VALUATION
overvalued / fair valued / undervalued
1..100
68
Overvalued
60
Fair valued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
9498
PRICE GROWTH RATING
1..100
3634
P/E GROWTH RATING
1..100
77100
SEASONALITY SCORE
1..100
n/an/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

PRME's Valuation (60) in the null industry is in the same range as CRSP (68) in the Biotechnology industry. This means that PRME’s stock grew similarly to CRSP’s over the last 12 months.

PRME's Profit vs Risk Rating (100) in the null industry is in the same range as CRSP (100) in the Biotechnology industry. This means that PRME’s stock grew similarly to CRSP’s over the last 12 months.

CRSP's SMR Rating (94) in the Biotechnology industry is in the same range as PRME (98) in the null industry. This means that CRSP’s stock grew similarly to PRME’s over the last 12 months.

PRME's Price Growth Rating (34) in the null industry is in the same range as CRSP (36) in the Biotechnology industry. This means that PRME’s stock grew similarly to CRSP’s over the last 12 months.

CRSP's P/E Growth Rating (77) in the Biotechnology industry is in the same range as PRME (100) in the null industry. This means that CRSP’s stock grew similarly to PRME’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
CRSPPRME
RSI
ODDS (%)
Bearish Trend 4 days ago
88%
Bearish Trend 4 days ago
90%
Stochastic
ODDS (%)
Bearish Trend 4 days ago
88%
Bearish Trend 4 days ago
89%
Momentum
ODDS (%)
N/A
N/A
MACD
ODDS (%)
Bullish Trend 4 days ago
73%
N/A
TrendWeek
ODDS (%)
Bullish Trend 4 days ago
76%
Bearish Trend 4 days ago
89%
TrendMonth
ODDS (%)
Bullish Trend 4 days ago
76%
Bullish Trend 4 days ago
75%
Advances
ODDS (%)
Bullish Trend 13 days ago
79%
Bullish Trend 12 days ago
78%
Declines
ODDS (%)
Bearish Trend 7 days ago
83%
Bearish Trend 5 days ago
88%
BollingerBands
ODDS (%)
Bearish Trend 4 days ago
81%
Bearish Trend 4 days ago
90%
Aroon
ODDS (%)
Bullish Trend 4 days ago
75%
Bullish Trend 4 days ago
82%
View a ticker or compare two or three
Interact to see
Advertisement
CRSP
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
PRME
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
TBLIX35.840.02
+0.06%
Transamerica Multi-Managed Balanced I
WSBFX22.66-0.01
-0.04%
Boston Trust Walden Balanced
LVPSX93.89-0.11
-0.12%
ProFunds Large Cap Value Svc
PXWGX24.44-0.04
-0.16%
Impax US Sustainable Economy Investor
JGMCX21.28-0.08
-0.37%
Janus Henderson Triton C

CRSP and

Correlation & Price change

A.I.dvisor indicates that over the last year, CRSP has been closely correlated with BEAM. These tickers have moved in lockstep 72% of the time. This A.I.-generated data suggests there is a high statistical probability that if CRSP jumps, then BEAM could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To CRSP
1D Price
Change %
CRSP100%
+18.22%
BEAM - CRSP
72%
Closely correlated
+1.47%
RXRX - CRSP
72%
Closely correlated
+5.80%
NTLA - CRSP
65%
Loosely correlated
+1.94%
CRBU - CRSP
64%
Loosely correlated
+12.02%
ALLO - CRSP
62%
Loosely correlated
+0.81%
More